Abstract
The current Singapore school-based national immunization program (NIP) includes bivalent HPV vaccine (2vHPV) for females 13 years of age. The 9-valent HPV vaccine (9vHPV) provides additional benefits through direct protection against seven additional HPV types. This study assesses the health impact and cost-effectiveness of 9vHPV for females and males (gender neutral vaccination; GNV) vs. 2vHPV for females only vaccination (FOV) immunization strategies accounting for potential cross-protection for 2vHPV.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
